Ola Soderquist - 31 Dec 2022 Form 5 Insider Report for BIOXYTRAN, INC (BIXT)

Reporting relationship: CFO, 10%+ Owner
Issuer ticker: BIXT
Reported as of: 31 Dec 2022
Net transaction value: -$38,681
SEC form: 5
Accepted by SEC: 08 Feb 2023, 10:40:03 UTC
Prior SEC filing: 13 May 2022
Next SEC filing: 17 May 2023
Source filing: View source filing
Reporting owner signature: Ola Soderquist

Key filing fact

Ola Soderquist filed Form 5 for BIOXYTRAN, INC (BIXT) on 08 Feb 2023.

Key facts

This page summarizes Ola Soderquist's Form 5 filing for BIOXYTRAN, INC (BIXT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Feb 2023, 10:40.

Change

Previous filing in this sequence was filed on 13 May 2022.
Current net transaction value: -$38,681.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIXT transaction

common

Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities

Transaction value: $2,681
Shares: -1,340,749
Change %: -100%
Price: $0.002000^*
Shares after: 0
Date: 31 Dec 2022
Ownership: by NDPD Pharma, Inc.
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIXT transaction Derivative

warrant

Gift

Transaction value: $36,000
Shares: -100,000
Change %: -100%
Price: $0.3600
Shares after: 0
Date: 13 May 2022
Ownership: by NDPD Pharma, Inc.
Underlying class: common
Underlying amount: 100,000
Exercise price: $2.00

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

ownership of BIXT by NDPD Pharma, Inc. is consolidated under indirect ownership inside Davis Platt's filing

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .